Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.260
-0.045 (-3.45%)
At close: Sep 30, 2026, 4:00 PM EDT
1.280
+0.020 (1.59%)
After-hours: Sep 30, 2026, 7:55 PM EDT
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,876,555
Market Cap
6.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2024 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Sep 30, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Dec 31, 2021 | 3 | 0 | - | 3 | 0 |
| Mar 31, 2021 | 3 | - | - | 2 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| Evogene | 38 |
| Bolt Biotherapeutics | 23 |
| Imunon | 20 |
| Processa Pharmaceuticals | 12 |
| Ensysce Biosciences | 10 |
| CNS Pharmaceuticals | 8 |
| Enveric Biosciences | 6 |
ACXP News
- 1 day ago - Acurx enrolls first patient in clinical trial of Ibezapolstat in rCDI - TheFly
- 1 day ago - Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection - PRNewsWire
- 16 days ago - Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. - PRNewsWire
- 22 days ago - Acurx Pharmaceuticals Registration statement: Registration filing - Filings
- 4 weeks ago - Acurx Pharmaceuticals Proxy statement: Proxy filing - Filings
- 4 weeks ago - Acurx Pharmaceuticals Proxy statement: Proxy filing - Filings
- 6 weeks ago - Acurx announces FDA conditional approval of CIFBEZY as brand name for ibezapolst - TheFly
- 6 weeks ago - Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat - PRNewsWire